

=> d his

(FILE 'HOME' ENTERED AT 13:28:11 ON 25 SEP 2006)

FILE 'EMBASE' ENTERED AT 13:28:19 ON 25 SEP 2006

L1 10064 S GANGLIOSIDE
L2 391 S L1 AND (SEPARATION OR PURIFICATION)
L3 31 S L2 AND HYDROLYSIS
L4 23 S L3 NOT PY>2001

FILE 'USPATFULL' ENTERED AT 13:32:30 ON 25 SEP 2006

L5 3003 S GANGLIOSIDE
L6 9 S L1 AND (SEPARATION/TI OR PURIFICATION/TI)

FILE 'REGISTRY' ENTERED AT 13:36:55 ON 25 SEP 2006

L7 STRUCTURE UPLOADED
L8 4 S L7
L9 33 S L7 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:39:10 ON 25 SEP 2006

L10 307 S L9
L11 7 S L10 AND GLYCOSYLATION
L12 1 S L9 AND LECITHIN

FILE 'BIOSIS, EMBASE' ENTERED AT 13:41:52 ON 25 SEP 2006

L13 18 S LECITHIN AND GLYCOPHINGO?
L14 0 S L13 AND HYDROLYSIS
L15 4 S L13 AND (SEPARATION OR ISOLATION OR PURIFICATION)

FILE 'USPATFULL' ENTERED AT 13:43:21 ON 25 SEP 2006

L16 1616 S GLYCOPHINGO?
L17 5 S L16 AND (PURIFICATION/TI OR SEPARATION/TI OR ISOLATION/TI)
L18 9 S L16 AND (PURIFICATION/TI OR SEPARATION/TI OR ISOLATION/TI)
L19 5 S L18 AND HYDROLYSIS

FILE 'REGISTRY' ENTERED AT 13:59:56 ON 25 SEP 2006

L20 STRUCTURE UPLOADED
L21 0 S L20
L22 20 S L20 SSS FULL

FILE 'CAPLUS' ENTERED AT 14:01:10 ON 25 SEP 2006

L23 6 S L22

FILE 'REGISTRY' ENTERED AT 14:15:37 ON 25 SEP 2006

FILE 'CAPLUS' ENTERED AT 14:27:49 ON 25 SEP 2006

L24 10 S L9 AND GLYCOSYLAT?

FILE 'REGISTRY' ENTERED AT 14:31:07 ON 25 SEP 2006

L25 1 S PARAGLOBOSIDE/CN

FILE 'CAPLUS' ENTERED AT 14:31:30 ON 25 SEP 2006

L26 270 S L25
L27 7 S L25/THU
L28 8 S L25/PREP
L29 7 S L26 AND ISOLATION
L30 5 S L26 AND ISOLATION/TI

FILE 'REGISTRY' ENTERED AT 15:11:44 ON 25 SEP 2006

L31 STRUCTURE UPLOADED
L32 1 S L31 FAM FULL

FILE 'CAPLUS' ENTERED AT 15:12:16 ON 25 SEP 2006


L33 1 S L32

FILE 'REGISTRY' ENTERED AT 15:12:53 ON 25 SEP 2006
L34 1 S GABAPENTIN/CN

FILE 'CAPLUS' ENTERED AT 15:13:10 ON 25 SEP 2006
L35 1404 S L34
L36 1069 S L34/THU
L37 27 S L36 AND (OSTEOARTHRITIS OR (CARTILAGE))
L38 0 S L37 NOT PY>2000
L39 1 S L37 NOT PY>2002
L40 7 S L36 AND CARTILAGE

=>

Uploading C:\Program Files\Stnexp\Queries\10602413verify.str



chain nodes :

7 8 9 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

ring nodes :

1 2 3 4 5 6 10 11 12 13 14

chain bonds :

1-23 1-24 2-25 2-26 3-27 3-28 4-29 4-30 5-7 5-20 6-21 6-22 7-8 7-10
7-17 8-9 8-18 8-19 11-15 12-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-14 11-12 12-13 13-14

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 10-11 10-14 11-12 12-13 12-16 13-14

exact bonds :

1-23 1-24 2-25 2-26 3-27 3-28 4-29 4-30 5-7 5-20 6-21 6-22 7-8 7-10
7-17 8-18 8-19 11-15

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS
29:CLASS 30:CLASS

L31 STRUCTURE UPLOADED

=> d l31

L31 HAS NO ANSWERS

L31 STR



Structure attributes must be viewed using STN Express query preparation.



```
=> s l31 fam full
FULL SEARCH INITIATED 15:12:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 16 TO ITERATE
```

```
100.0% PROCESSED      16 ITERATIONS      1 ANSWERS
SEARCH TIME: 00.00.01
```

```
L32      1 SEA FAM FUL L31
```

```
=> d l32
```

```
L32  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   758697-34-6  REGISTRY
ED   Entered STN:  08 Oct 2004
CN   1,2,4-Oxadiazol-5(2H)-one, 3-(2-amino-1-cyclohexylethyl)- (9CI)  (CA INDEX
NAME)
MF   C10 H17 N3 O2
SR   CA
LC   STN Files:   CA, CAPLUS, USPATFULL
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
67.59	558.96

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-17.25

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 15:12:16 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 24 Sep 2006 (20060924/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l32

L33 1 L32

=> d l33 ti abs bib

L33 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of tetrazole and oxadiazolone substituted β -amino acid derivatives as ligands of the $\alpha 2\delta$ -subunit of a calcium channel
AB Title compds. R2R1(NH2)C-C(G)R3R4 [G = tetrazolyl, 1,3,5-oxadiazol-2-one; R1-2 = H, alkyl, alkoxy, etc.; R3-4 = H, Me; (I)] and related cyclopropane derivs. are prepared For instance, 4-methyl-2-(1H-tetrazol-5-yl)pentylamine is prepared from 1-benzyl-1H-tetrazole and 4-methyl-1-nitropentene in 2 steps. Selected example compds. exhibit binding with nM to μ M affinity for $\alpha 2\delta$ -subunit of the calcium channel (3 biol. examples). I are useful for the treatment of central nervous system and other disorders.
AN 2004:756699 CAPLUS <<LOGINID::20060925>>
DN 141:277627
TI Preparation of tetrazole and oxadiazolone substituted β -amino acid derivatives as ligands of the $\alpha 2\delta$ -subunit of a calcium channel
IN Barta, Nancy Sue; Colbry, Norman Lloyd; Hudack, Raymond Andrew, Jr.; Lin, Kristin Knapp; Schwarz, Jacob Bradley; Thorpe, Andrew John; Wustrow, David Juergen; Zhu, Zhijian
PA Warner-Lambert Company LLC, USA
SO PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004078734	A1	20040916	WO 2004-IB510	20040223
	WO 2004078734	C1	20051215		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	CA 2518218	AA	20040916	CA 2004-2518218	20040223
	EP 1603890	A1	20051214	EP 2004-713604	20040223
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2004008110	A	20060301	BR 2004-8110	20040223
	JP 2006519831	T2	20060831	JP 2006-506264	20040223
	US 2005014804	A1	20050120	US 2004-795760	20040308
PRAI	US 2003-452871P	P	20030307		
	WO 2004-IB510	W	20040223		

OS MARPAT 141:277627

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file registry

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
3.20	562.16

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.75	-18.00

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 15:12:53 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8
DICTIONARY FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s gabapentin/cn
L34 1 GABAPENTIN/CN

=> d 134

L34 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 60142-96-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN Cyclohexaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-(Aminomethyl)cyclohexaneacetic acid
CN CI 945
CN Gabapentin
CN Go 3450
CN GOE 2450
CN GOE 3450
CN Neurontin
MF C9 H17 N O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM,
DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS,
IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT,
PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, .
USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1401 REFERENCES IN FILE CA (1907 TO DATE)
46 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1404 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
7.10	569.26

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-18.00

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 15:13:10 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 24 Sep 2006 (20060924/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l34

L35 1404 L34

=> s l34/thu

1404 L34

814465 THU/RL

L36 1069 L34/THU

(L34 (L) THU/RL)

=> s l36 and (osteoarthritis or (cartilage))

8177 OSTEOARTHRITIS

25383 CARTILAGE

L37 27 L36 AND (OSTEOARTHRITIS OR (CARTILAGE))

=> s l37 not py>2000

6290614 PY>2000

L38 0 L37 NOT PY>2000

=> d l37 1-27 ti

L37 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN

TI 1,3-Disubstituted heteroaryl derivatives as NMDA/NR2B antagonists, their preparation, pharmaceutical compositions, and use in therapy

L37 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of nitroxyalkyl derivatives of phenol for treating inflammatory, cardiovascular and peripheral vascular diseases

L37 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN

TI Novel dosage form comprising modified-release and immediate-release active ingredients

L37 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN

TI The Effects of Diacerhein on Mechanical Allodynia in Inflammatory and Neuropathic Models of Nociception in Mice

L37 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN

TI Crystalline polymorphs of a CXC-chemokine receptor ligand

L37 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of isothiazole dioxides as CXC- and CC-chemokine receptor ligands

L37 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of diaminothiadiazoles as CXC- and CC-chemokine receptor ligands

L37 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN

TI Method of biochemical treatment of persistent pain by inhibiting

biochemical mediators of inflammation

- L37 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification, and management of pain
- L37 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods of using and compositions comprising selective cytokine inhibitory drug for treatment, modification and management of pain
- L37 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Compositions treatment of chronic inflammatory diseases
- L37 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
- L37 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Adenosine derivatives for the treatment of pain
- L37 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Tetracycline compounds having target therapeutic activities
- L37 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Treatment of pain with spongostin
- L37 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
- L37 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods and compositions using selective cytokine inhibitory drugs, alone or in combination with other therapeutic means, for treatment, modification and management of pain
- L37 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
- L37 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
- L37 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Tetracycline compounds having target therapeutic activities
- L37 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Treating nerve pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels (HCN)
- L37 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Chondroprotective/restorative compositions containing hyaluronic acid
- L37 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method of treating cartilage damage
- L37 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors
- L37 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods of using and compositions comprising (+)-sibutramine optionally in combination with other pharmacologically active compounds

L37 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds

L37 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Isobutyl-GABA and its derivatives for the treatment of pain

=> s 137 not py>2002
4373464 PY>2002
L39 1 L37 NOT PY>2002

=> d 139 ti abs bib

L39 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
AB This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compns. and dosage forms which comprise optically pure (-) sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor. A solution of 21.7 g L-dibenzyltartaric acid ("L-DBTA") in Et acetate was added to a solution of 12.3 g racemic sibutramine in Et acetate and the reaction mixture was heated to reflux and cooled to room temperature. The white precipitate was collected and the solid was then suspended in Et acetate and heated at reflux for 30 min. The solid was collected and further crystallized in iso-Pr alc. to give 11.3 g of (-)-sibutramine L-DBTA (yield 76%). Free base was obtained by treatment of (-)-sibutramine L-DBTA with saturated aqueous NaHCO₃ and extracted with chloroform.

A pharmacol. study was conducted to determine the relative potency, comparative efficacy, binding affinity, and toxicity of the enantiomers and racemic mixture of sibutramine. A capsule contained (-) sibutramine 10.0, lactose 70.0, corn starch 19.5, and magnesium stearate 0.05 mg.

AN 2002:51988 CAPLUS <<LOGINID::20060925>>
DN 136:107551
TI Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
IN Young, James W.; Jerussi, Thomas P.
PA USA
SO U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 721,669.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002006963	A1	20020117	US 2001-770665	20010129
	WO 2002060428	A2	20020808	WO 2002-US2039	20020123
	WO 2002060428	A3	20021219		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 1992-903040 B1 19920623
US 1995-461608 B1 19950605
US 2000-721669 A2 20001127
US 2001-770665 A 20010129

=> s l36 and cartilage
25383 CARTILAGE
L40 7 L36 AND CARTILAGE

=> d l40 1-7 ti

L40 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Novel dosage form comprising modified-release and immediate-release active ingredients

L40 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor

L40 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Tetracycline compounds having target therapeutic activities

L40 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2

L40 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Tetracycline compounds having target therapeutic activities

L40 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Chondroprotective/restorative compositions containing hyaluronic acid

L40 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method of treating cartilage damage